logo
Share SHARE
FONT-SIZE Plus   Neg

Abbott Selects AbbVie As New Name For Future Research-Based Pharma Co.

Abbott (ABT: Quote) announced that AbbVie will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012.

AbbVie, the research-based pharmaceutical company, will include Abbott's current portfolio of leading proprietary pharmaceuticals and biologics. The diversified medical products company, which will retain the Abbott name, will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostics and nutritional businesses.

Further, Richard Gonzalez, currently executive vice president, Global Pharmaceuticals, will become chairman and CEO of AbbVie. However, Miles White will remain chairman and CEO of Abbott.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
We are just a few weeks into 2015 and it has already been a busy year for merger deals and merger talks. Here is a list of some of the M&A stories that have made headlines so far in 2015. Diversified electronics maker TE Connectivity Ltd. is nearing a deal to sell its network solutions business unit to CommScope Holding Co., Inc. (COMM) in a deal valued at about $3 billion, according a Wall Street Journal report on Monday. A deal could be announced as early as this week. There has... The video game industry waltzed through 2014 with a record $24 billion in acquisitions and IPOs, says advisory firm Digi-Capital. The frenzied activity in the industry came as companies vied to get hold of game titles that could tilt the scale in their favor, and the need to shore up investment in infrastructure and marketing.
comments powered by Disqus
Follow RTT